Why the study?
To compare the performance of pulmonary homografts with stentless bioprosthetic valves in the pulmonary position in patients with congenital heart disease younger than 20 years.
Do stentless bioprosthetic valves compared to pulmonary homografts improve freedom from reintervention and structural valve degeneration in patients younger than 20 years with congenital heart disease?
Do stentless bioprosthetic valves compared to pulmonary homografts improve freedom from reintervention and structural valve degeneration in patients younger than 20 years with congenital heart disease?
Answers are grounded in this paper and cite their sources.
Stentless bioprosthetic valves are a comparable alternative to pulmonary homografts for up to 10 years in pediatric and young adult patients, but are associated with significantly higher rates of reintervention and structural degeneration thereafter.
OBJECTIVES: The aim of this study was to compare the performance of pulmonary homografts with stentless bioprosthetic valves [Medtronic Freestyle™ (Medtronic, Minneapolis, MN, USA)] in the pulmonary position in patients with congenital heart disease (CHD) younger than 20 years. METHODS: Between January 2000 and December 2017, 215 patients were retrospectively identified from hospital databases in 3 congenital heart centres in Australia. Valve performance was evaluated using standard criteria. Propensity score matching was used to balance the 2 treatment groups. RESULTS: Freedom from reintervention for patients who received a pulmonary homograft (n = 163) was 96%, 88% and 81% at 5, 10 and 15 years and for patients who received a Freestyle™ valve (n = 52) was 98%, 89% and 31% at 5, 10 and 15 years, respectively. Freedom from structural valve degeneration for patients with a homograft was 92%, 87% and 77% at 5, 10 and 15 years and for patients with a Freestyle valve was 96%, 80% and 14% at 5, 10 and 15 years, respectively. In the first 10 years, there was no difference in outcomes [reintervention hazard ratios (HR) = 0.69, 95% confidence intervals (CI) (0.20-2.42), P = 0.56; structural valve degeneration HR = 0.92 (0.34-2.51), P = 0.87]. After 10 years, the recipients of the Freestyle valves were at higher risk of both outcomes [reintervention HR = 7.89; 95% CI (2.79-22.34), P < 0.001; structural valve degeneration HR = 7.41 (2.77-19.84), P < 0.001]. The findings were similar when analysed by implantation in the orthotopic position and in the propensity-matched groups. CONCLUSIONS: The Freestyle stentless bioprosthetic valve is a comparable alternative to cryopreserved pulmonary homografts up to 10 years after implantation when implanted in an orthotopic pulmonary position in patients younger than 20 years with CHD.
No takes yet. Share an insight, caveat, or question.
Marathe et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: